ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy.

MLA

Okada, Masahiro, et al. “ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy.” Cancer Research, vol. 84, no. 17, Sept. 2024, pp. 2792–805. EBSCOhost, https://doi.org/10.1158/0008-5472.CAN-23-2846.

APA

Okada, M., Yamasaki, S., Nakazato, H., Hirahara, Y., Ishibashi, T., Kawamura, M., Shimizu, K., & Fujii, S.-I. (2024). ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy. Cancer Research, 84(17), 2792–2805. https://doi.org/10.1158/0008-5472.CAN-23-2846

Chicago

Okada, Masahiro, Satoru Yamasaki, Hiroshi Nakazato, Yuhya Hirahara, Takuya Ishibashi, Masami Kawamura, Kanako Shimizu, and Shin-Ichiro Fujii. 2024. “ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy.” Cancer Research 84 (17): 2792–2805. doi:10.1158/0008-5472.CAN-23-2846.